Florian Kemmerich MSc - Chairman of Board of Directors
Florian is Managing Partner at Bamboo Capital, Founder of Ryan-Kay, Advisor of several investment funds and Board Member of numerous organisations. He holds a Bachelor of Business Administration, Master of Science and different diploma on executive and personal development. As a corporate advisor and CEO mentor he leverages his extensive background on start-ups in biotech, medical device and life science to help building and positioning organisations in the competitive global marketplace.
Passionate about translational science, disruptive technologies, fundraising and global life sciences. Prized for building a major international business leader network for small and medium enterprises in healthcare and life sciences. Valued for successful problem solving by primarily crafting the vision, assessing unmet market needs, designing directed strategies and attracting the required (human) capital. Comfortable, proficient and valuable in global intercultural management with a deep understanding of the industry along with a solid knowledge of market dynamics and cultures.
With over 25 years in life sciences Florian held C-level positions at B. Braun Medical, Olympus Biotech, Small Bone Innovations (now Stryker) and lead several early & commercial stage startups. Fluent in German, English, Spanish, French, Italian.
Su Metcalfe MA PhD (Cantab) - Chief Executive Officer, Founder, and President
Awarded Business Woman of the Year 2017, Cambridge, and recipient of the Global Nanomedicine Award 2017, Su is founder of LIFNano Therapeutics. Driven by the need to "heal the brain" in a world where dementia is an emerging global epidemic, Su has brought her invention of LIFNano - a nanotherapeutic device able to replace stem cells - to the clinic. LIFNano behaves as an artificial stem cell with powerful properties for Brain Health. These properties are captured using nanotechnology with LIFNano a world leader in the new era of NANOMEDICINE. Proven safe and effective, clinical trials of LIFNano are due in 2020 to treat Multiple Sclerosis.
Su's trajectory from Bench-2-Bedside follows a career in neuro-immune research at the University of Cambridge where she discovered that LIF plays a core role in immunity, not only to prevent pathogenic inflammation, but also to repair damaged tissues throughout life.
· Recipient I-UK Biomedical Catalyst award 2016 - 2018 to develop LIFNano to treat MS (£1 million)
· Member Cambridge University Judge Business School
· Member Cambridge University Biomedical Campus
Andrew Wood - Chief Financial Officer
1st Class Hons Oxford (Biochemistry). Andrew has extensive finance and commercial experience in startup, early stage and established businesses. He is now building a portfolio of early stage life sciences companies. Previously he was CFO of Oxford Biomedica.
Commercial, Scientific and Clinical Advisors
Senior Director, Scientific & Project Management & Clinical Programme Director for AZD5363, Astra Zeneca; AZ Representative on the Experimental Medicine Expert Network of the ABPI
Assoc. Dir. Business Strategy & Operations
Regulatory Affairs International
Merck Sharp & Dohme
Professor Tarek Fahmy
Yale University: Associate Professor of Biomedical Engineering and Immunobiology
Previous: Vice President Regulatory Affairs, Astra Zeneca
Vice President, Business & Commercial Development, Astellas
Professor Sir Mark Welland
University of Cambridge: Professor of Nanotechnology and Head of the Nanoscience Centre
Head of NeuroImmunology, EMD Serono Inc.
Professor Giovanni Tosi
University of Modena and Reggio Emilia
Professor of Neurology, Barts and the London School of Medicine and Dentistry
Senior Business Development in cGMP manufacture of therapeutic biologics
Professor Niels Hellings
Hasselt University, Belgium: Associate Professor Immunology and Vice-Director of Biomed